Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc.
1:16-cv-00999
Overview
Parties
Defendant
Plaintiff
Onyx Therapeutics, Inc. Operating Company
Represented By
6 Attorneys ListedO'Melveny & Myers LLP
7 Times Square, Times Square Tower, New York, NY 10036
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Onyx Therapeutics, Inc. v. InnoPharma Inc.
Onyx Therapeutics, Inc. v. Dr. Reddy's Laboratories, Inc.
Onyx Therapeutics, Inc. v. Sagent Pharmaceuticals, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7737112
Composition for enzyme inhibition
|
Filed: 2005-12-07
Issued: 2010-06-15
|
Active (1.1 yrs remaining)
+742d PTA
Expires: 2027-12-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+742 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings